Anthem Biosciences
655.35
-12.55(-1.88%)
Market Cap₹36,805.11 Cr
PE Ratio72.71
IndustryHealthcare
Company Performance:
1D-1.88%
1M+3.74%
6M-10.27%
1Y-10.27%
5Y-10.27%
View Company Insightsright
More news about Anthem Biosciences
18Aug 25
Anthem Biosciences Reports Strong Q1 FY26 Results with 60% Revenue Growth
Anthem Biosciences Limited reported robust Q1 FY26 results, with consolidated revenue reaching INR 540.00 crores, a 60% year-on-year growth. EBITDA stood at INR 214.30 crores with a 38% margin, while PAT was INR 135.80 crores with a 24% margin. The company added two commercial molecules and expanded its custom synthesis capacity. Anthem Biosciences maintains a strong pipeline with 8 molecules in Phase 3 trials and plans further capacity expansion across its units. The management expects to maintain historical growth rates of around 20% annually, despite this quarter's exceptional performance.
13Aug 25
Anthem Biosciences Reports Strong Q1 Results Amid Expansion Efforts
Anthem Biosciences, a leading CRDMO, reported robust Q1 financial results. Consolidated Revenue from Operations increased by 59.5% to ₹5,402.09 crore. EBITDA reached ₹2,143.00 crore with a 38% margin. PAT grew by 64.8% to ₹1,358.00 crore. The CRDMO segment contributed 83.8% of total revenue. The company is expanding its capabilities in API, intermediates, formulation, biologics, and specialty chemistry services. Operational expansions include new facilities at Unit II and Unit III in Harohalli, with construction beginning on a greenfield facility at Unit IV.
13Aug 25
Anthem Biosciences Reports Strong Q1 Results with 59.5% Revenue Growth
Anthem Biosciences, a leading CRDMO, announced robust Q1 FY24 results. Consolidated revenue increased by 59.5% to ₹5,402.09 million. EBITDA grew 52.7% to ₹2,143.00 million, with a 39.67% margin. PAT rose 64.8% to ₹1,357.91 million. The CRDMO segment saw 70.5% growth, while Specialty Ingredients grew 19.7%. The company completed capacity expansions, inaugurated new facilities, and maintained a strong net cash position of ₹7,848.00 million. Anthem recently completed its IPO and was listed on NSE and BSE.
22Jul 25
Anthem Biosciences Appoints Divya Prasad as Company Secretary and Compliance Officer
Anthem Biosciences Limited has appointed Ms. Divya Prasad as Company Secretary and Compliance Officer, effective October 18, 2024. Ms. Prasad, with ICSI Membership No: A41438, will also serve as Compliance Officer under SEBI regulations. The company has implemented various measures to ensure regulatory compliance, including appointing KFin Technologies Limited as Registrar & Share Transfer Agent and maintaining a structured digital database for unpublished price-sensitive information. A trading window closure has been announced from July 21, 2025, until 48 hours after the declaration of Q2 2025 financial results.
21Jul 25
Anthem Biosciences Shares Soar 27% on Stock Market Debut
Anthem Biosciences Limited made a strong market debut with shares opening at ₹723.05, a 27% premium over its IPO price of ₹570. This represents a gain of ₹153.05 per share for IPO investors. The impressive listing suggests investor confidence in the company's potential and reflects broader interest in the biosciences sector.
Anthem Biosciences
655.35
-12.55
(-1.88%)
1 Year Returns:-10.27%
Industry Peers
Anthem Biosciences
655.35
(-1.88%)
Advanced Enzyme Tech
300.00
(-2.49%)
Genesis IBRC
93.85
(0.0%)
Vivo Bio Tech
32.70
(+2.00%)